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This Month in the Journal
TMD Is Caused by Mutations in Titin, by Hackman et
al. (p. 492)
Hackman et al. add the gene for titin (TTN) to the list
of genes involved in muscular dystrophy, with their find-
ing of mutations in individuals with tibial muscular dys-
trophy (TMD). Titin is a giant, filamentous muscle pro-
tein that is essential for muscle structure, development,
and elasticity. It also possesses several ligand-binding
sites for muscle proteins and may serve as a blueprint
for sarcomere assembly. Immunofluorescence, using anti-
bodies to specific epitopes within titin, suggests that, at
least for one of the two mutations identified in this work,
a large portion of the titin structure is intact but that
the C-terminus is disrupted. There are many titin regions
that are differentially expressed in differentmuscle types.
This may be one reason behind the localization ofmuscle
weakness and atrophy in TMD to the anterior com-
partment of the lower leg. However, it does not explain
why TMD patients do not have cardiomyopathy, even
though the portion of titin that is disrupted by the mu-
tations in this study is expressed in cardiac muscle. An-
other potential explanation for the muscle specificity of
TMD is the loss, in titin, of binding sites for muscle-
specific binding proteins. As a protein interaction site
for calpain3 is in the mutated region of TTN and as
calpain3 is not expressed in mature heart muscle, the
authors speculate that alteration of the titin-calpain3
interaction may partly explain the TMD disease mech-
anism and its muscle specificity.
IAHSP and Alsin, by Eymard-Pierre et al. (p. 518)
Eymard-Pierre et al. increase the range of phenotypes
associated with mutations in the gene for alsin (ALS2),
with their finding of ALS2 mutations in families with
infantile early-onset ascending hereditary spastic paral-
ysis (IAHSP). IAHSP is a severe spastic paralysis with
an ascending progression. ALS2 mutations were previ-
ously reported in juvenile amyotrophic lateral sclerosis
and in familial juvenile-onset primary lateral sclerosis,
which are similar neurodegenerative disorders that affect
the upper and lower motor neurons, to different extents.
The function of alsin is unknown. There are two alter-
natively spliced variants of the ALS2 transcript, and it
has been proposed that ALS2 mutations that disrupt
only the longer form of the alsin protein result in amilder
phenotype. However, Eymard-Pierre et al. did not find
evidence for a genotype-phenotype correlation; muta-
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tions in either form of alsin gave rise to similar disease
phenotypes and progression in their sample.
HLA Class II Risk Haplotypes in SLE, by Graham et
al. (p. 543)
Although associations of the HLA region with systemic
lupus erythematosus (SLE) have been found, it has been
difficult to dissect this association further, because of ex-
tensive linkage disequilibrium (LD) in this region.Graham
et al. managed to do this by typing, in a large set of
families with SLE, a dense set of microsatellites across the
HLA region. Three haplotypes exhibited transmissiondis-
tortion and were enriched in case individuals compared
with control individuals. These haplotypes contain the
DRB1*1501/DQB1*0602, DRB1*0801/DQB1*0402,
and DRB1*0301/DQB1*0201 alleles. The families that
carried one or more of these risk haplotypes accounted
for almost all of the transmission distortion observed in
this region. By determining the ancestral risk haplotypes
containing the risk alleles, the authors were able to limit
the risk interval around DRB1*0801 and DRB*0501 to
an interval of ∼500-kb that contains DRB1 and DQB1
but excludes the class I and class III regions, including
TNF-a. In fact, there are only two other genes in this
interval, and they are of unknown function. The HLA
class II haplotypes containing theDRB1 andDQB1 alleles
thus appear to be strong risk factors for SLE.
LD Mapping of BP-1 in Costa Rica, by Ophoff et al.
(p. 565)
Ophoff et al. report the results of a genomewide LD
mapping study for severe bipolar disorder. They geno-
typed 11,000 STRmarkers in a young population isolate
from the central valley of Costa Rica (CVCR) that has
previously been demonstrated to have extensive LD.
The goal was to identify haplotypes that were shared
more frequently by affected individuals than would be
expected by chance. Several markers were overrepre-
sented in affected individuals, with one region particu-
larly standing out: marker alleles and haplotypes in a
22-cM region on chromosome 8p showed evidence of
association( with bipolar disorder, when analyzed using
two different statistical methods. At this stage, the de-
velopment of this LD mapping strategy is still in its in-
fancy, and it is not clear how corrections for multiple
testing should be applied to these data to assess the sta-
tistical significance of the findings. Rather than using
this method to identify statistically significant associa-
tions, the authors propose that this type of strategy be
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used to prioritize the genetic regions that should be fur-
ther studied, using additional samples and methods.
BRCA2 T2722R Is a Deleterious Allele That Causes
Exon Skipping, by Fackenthal et al. (p. 625)
Although a large number of predicted missense poly-
morphisms have been found in BRCA1 and BRCA2, it
has been impossible to characterize most of these vari-
ants because of the lack of standard, functional assays
for the BRCA proteins. It is therefore not clear whether
these variants are deleterious mutations that can lead to
breast and ovarian cancer. Fackenthal et al. decided to
determine whether they could classify any exonic single-
base BRCA2 substitutions through use of sequence ma-
trices that predict the disruption of exonic splicing–
enhancer (ESE) sequences. The analysis predicts that the
BRCA2 T2722R allele, a CrG transversion that segre-
gates with disease in an affected family, disrupts three
potential ESE sites, thereby leading to exon skipping.
This is confirmed in an individual carrying T2722R,who
is found to produce a BRCA2 transcript that lacks exon
18 and that is predicted to encode a functionally null,
truncated protein. The authors hope that this and other
predictive models can be used to characterize additional
BRCA1 and BRCA2 variants, to determine their clinical
significance.
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